| A569 |
Revdofilimab Biosimilar（Anti-TNFRSF4 / OX40 / CD134 Reference Antibody）
Featured
|
Revdofilimab (ABBV-368) is a human IgG1 agonist monoclonal antibody against OX40. Among them, OX40 is a member of the TNF receptor superfamily expressed on activated and memory T cell subsets and T regulatory cells. |
|
| A570 |
Tavolixizumab Biosimilar（Anti-TNFRSF4 / OX40 / CD134 Reference Antibody）
Featured
|
Tavolixizumab (MEDI 0562; Tavolimab) is a human monoclonal antibody to TNFRSF4 (TNF receptor superfamily member 4) for use in cancer immunology research. |
|
| A571 |
Telazorlimab Biosimilar（Anti-TNFRSF4 / OX40 / CD134 Reference Antibody）
Featured
|
Telazorlimab (GBR-830) is a humanized monoclonal antibody against OX40 costimulatory receptor on activated T cells. Telazorlimab can be used for the research of autoimmune diseases. |
|
| A572 |
BMS-986178 Biosimilar（Anti-TNFRSF4 / OX40 / CD134 Reference Antibody）
Featured
|
|
|
| A573 |
Ivuxolimab Biosimilar（Anti-TNFRSF4 / OX40 / CD134 Reference Antibody）
Featured
|
Ivuxolimab is an OX40 (also known as CD134; TNFRSF4) agonist monoclonal antibody. OX40 is a costimulatory receptor expressed on activated CD4+ and CD8+ T cells. Ivuxolimab shows antitumor activity, with potential immunostimulatory activity. |
|
| A574 |
Cudarolimab Biosimilar（Anti-TNFRSF4 / OX40 / CD134 Reference Antibody）
Featured
|
Cudarolimab (IBI101) is a completely human anti-OX40 (CD134, a co stimulating molecule expressed by activated immune cells) antibody. Cudarolimab inhibits the binding of OX40 to its ligand OX40L. Cudarolimab has antitumor activity and can be used in cancer related research. |
|
| A575 |
vonlerizumab Biosimilar（Anti-TNFRSF4 / OX40 / CD134 Reference Antibody）
Featured
|
|
|
| A576 |
Sotigalimab Biosimilar（Anti-TNFRSF5 / CD40 Reference Antibody）
Featured
|
Sotigalimab, a CD40 agonistic monoclonal antibody. Sotigalimab binds CD40 with high affinity and activates antigen-presenting cells, thereby stimulating cancer-specific T cell responses. Sotigalimab is mainly used in the study of metastatic pancreatic cancer and metastatic melanoma. |
|
| A577 |
Selicrelumab Biosimilar（Anti-TNFRSF5 / CD40 Reference Antibody ）
Featured
|
Selicrelumab is an agonist CD40 antibody, induces changes in the tumor microenvironment. Selicrelumab can be used for the research of pancreatic cance and neoadjuvant study. |
|
| A578 |
Dacetuzumab Biosimilar（Anti-TNFRSF5 / CD40 Reference Antibody）
Featured
|
Dacetuzumab (SGN-40) is a humanized IgG1, anti-CD40 monoclonal antibody with anti-lymphoma activity. Dacetuzumab kills tumor cells via immune effector functions (antibody-dependent cellular cytotoxicity and phagocytosis [ADCC/ADCP]). Dacetuzumab ((SGN-40) can be used for multiple myeloma research. |
|
| A579 |
Ravagalimab Biosimilar（Anti-TNFRSF5 / CD40 Reference Antibody）
Featured
|
Ravagalimab (ABBV-323) is a CD40 antagonist (EC50: 3.7 nM). Ravagalimab can be used for research of Crohn's disease. |
|
| A580 |
Lucatumumab Biosimilar（Anti-TNFRSF5 / CD40 Reference Antibody）
Featured
|
Lucatumumab (HCD122) is a fully human anti-CD40 antagonist monoclonal antibody, which blocks CD40/CD40L-mediated signaling. Lucatumumab efficiently mediates antibody-dependent cell-mediated cytotoxicity (ADCC) and clearance of tumor cells, can be used for refractory lymphomas, CLL and multiple myeloma research. |
|
| A581 |
Giloralimab Biosimilar（Anti-TNFRSF5 / CD40 Reference Antibody）
Featured
|
Giloralimab (ABBV-927) is a potent antiCD40 agonistic monoclonal antibody. Giloralimab has the potential for the research of cancer. |
|
| A582 |
Iscalimab Biosimilar（Anti-TNFRSF5 / CD40 Reference Antibody）
Featured
|
Iscalimab (CFZ-533) is a non-depleting IGg1 monoclonal antibody targeting CD40 (KD: 0.3 nM). Iscalimab can be used for research of Graves' hyperthyroidism and autoimmune diseases. |
|
| A583 |
Bleselumab Biosimilar（Anti-TNFRSF5 / CD40 Reference Antibody）
Featured
|
Bleselumab (ASKP 1240) is a human anti-CD40 monoclonal antibody (mAb). Bleselumab binds to human CD40 with high affinity (Kd: ?0.24?nM). Bleselumab inhibits immune responses by blocking the interaction of CD40 with its ligand CD40L. Bleselumab prevents organ transplant rejection. |
|
| A584 |
Mitazalimab Biosimilar（Anti-TNFRSF5 / CD40 Reference Antibody）
Featured
|
Mitazalimab (ADC-1013; JNJ-64457107) is FcγR-dependent CD40 agonist with tumor-directed activity. Mitazalimab activates antigen-presenting cells, e.g. dendritic cells (DC), to initiate tumor-reactive T cells. Therefore, Mitazalimab induces tumor-specific T cells to infiltrate and kill tumors. Mitazalimab remodels the tumor-infiltrating myeloid microenvironment. |
|
| A585 |
Emory U. anti-CD40 Biosimilar（Anti-TNFRSF5 / CD40 Reference Antibody）
Featured
|
|
|
| A586 |
Varlilumab Biosimilar（Anti-TNFRSF7 / CD27 Reference Antibody）
Featured
|
Varlilumab (CDX-1127) is a first-in-class human IgG1 anti-CD27 monoclonal antibody. Varlilumab has an anti-tumor activity. |
|
| A587 |
Organon patent anti-CD27 Biosimilar（Anti-TNFRSF7 / CD27 Reference Antibody）
Featured
|
|
|
| A588 |
Brentuximab Biosimilar（Anti-TNFRSF8 / CD30 Reference Antibody）
Featured
|
Brentuximab is a monoclonal antibody targeting CD30. Brentuximab is conjugated with monomethyl auristatin E (MMAE) (HY-15162) to form the antibody-drug conjugate Brentuximab vedotin (HY-P99107), which can induce apoptosis in primary effusion lymphoma cells. Brentuximab vedotin exhibits antitumor activity with an IC50 of 10 nM against human CD30+ cancer cells. |
|
| A589 |
Utomilumab Biosimilar(Anti-TNFRSF9 / 4-1BB / CD137 Reference Antibody)
Featured
|
Utomilumab (PF 05082566) is a fully human IgG2 mAb agonist of the T-cell costimulatory receptor 4-1BB/CD137. Utomilumab can be used for the research of relapsed/refractory follicular lymphoma (FL) and other CD20+ non-Hodgkin lymphomas (NHL). |
|
| A590 |
Urelumab Biosimilar(Anti-TNFRSF9 / 4-1BB / CD137 Reference Antibody)
Featured
|
Urelumab, a fully human, non-ligand binding, CD137 agonist IgG4 monoclonal antibody, enhances T-cell and natural killer-cell antitumor activity, and may enhance cytotoxic activity of Rituximab (HY-P9913). Urelumab can be used for the research of diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and other types of non-Hodgkin lymphoma (NHL). |
|
| DC67108 |
CMP-5 HCl
Featured
|
CMP-5 HClis a potent, specific, and selective PRMT5 inhibitor, while displays no activity against PRMT1, PRMT4, and PRMT7 enzymes. CMP-5 dihydrochloride selectively blocks S2Me-H4R3 by inhibiting PRMT5 methyltransferase activity on histone preparations. CMP-5 dihydrochloride prevents EBV-driven B-lymphocyte transformation but leaving normal B cells unaffected. |
.gif)
|
| A591 |
RO5458640 Biosimilar(Anti-TNFSF12 / TWEAK Reference Antibody)
Featured
|
|
|
| A592 |
Sibeprenlimab Biosimilar(Anti-TNFSF13 / APRIL / CD256 Reference Antibody）
Featured
|
Sibeprenlimab (VIS649) is a humanized IgG2 monoclonal antibody which inhibits a proliferation-inducing ligand (APRIL). Sibeprenlimab suppresses pathogenic immunoglobulins (IgA and IgM), while preserving antibody responses to mRNA-based vaccines against SARS-COV-2. Sibeprenlimab reduces urinary protein-to-creatinine ratio (UPCR) and glomerular filtration rate (GFR). Sibeprenlimab is promising for the research of IgA nephropathy (IgAN). |
|
| DC67109 |
Fluorescent-SM102
Featured
|
|
|
| A593 |
Zigakibart Biosimilar（Anti-TNFSF13 / APRIL / CD256 Reference Antibody）
Featured
|
Zigakibart (BION-1301) is an IgG4-kappa, anti-TNFSF13 (tumor necrosis factor (TNF) superfamily member 13, APRIL, CD256) humanized monoclonal antibody. Zigakibart shows anti-inflammatory activity. |
|
| A594 |
Tabalumab Biosimilar（Anti-TNFSF13B / BAFF / CD257 Reference Antibody）
Featured
|
Tabalumab (LY2127399) is a human anti-BAFF (B-cell activating factor) monoclonal antibody (IgG4 type) with neutralising activity against membrane bound and soluble BAFF. Tabalumab can be used in studies of autoimmune diseases such as rheumatoid arthritis, renal failure and systemic lupus erythematosus. |
|
| A595 |
Belimumab Biosimilar（Anti-TNFSF13B / BAFF / CD257 Reference Antibody）
Featured
|
Belimumab (LymphoStat B) is a humanized IgG1λ monoclonal antibody against B-lymphocyte stimulator (BLyS) protein. Belimumab antagonizes BLyS activity in autoimmune diseases and B-lymphocyte malignancies. Belimumab can be used for systemic lupus erythematosus (SLE) research. |
|
| A596 |
Quisovalimab Biosimilar（Anti-TNFSF14 / LIGHT / CD258 Reference Antibody）
Featured
|
Quisovalimab (AVTX-002; AEVI 002; SAR 252067) is a human monoclonal antibody against LIGHT, a tumor necrosis factor (TNF)-related cytokine (TNFSF14) that plays an important role in acute respiratory distress syndrome (ARDS) and cytokine release syndrome (CRS) COVID-19. Quisovalimab can be used in COVID-19 acute respiratory distress syndrome and other studies. |
|
